Bismuth antimicrobial drugs serve as broad-spectrum metallo-β-lactamase inhibitors

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  Wang, Runming ^a   Lai, Tsz Pui ^a   Gao, Peng ^a,b   Zhang, Hongmin ^a,c   Ho, Pak Leung ^a,b,d   Woo, Patrick Chiu Yat ^a,b,d   Ma, Guixing ^c   Kao, Richard Yi Tsun ^a,b,d   Li, Hongyan ^a   Sun, Hongzhe ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; BISMUTH CITRATE; BISMUTH DERIVATIVE; COLLOIDAL BISMUTH COMPOUND; MEROPENEM; METALLO BETA LACTAMASE; ZINC ION; BETA LACTAMASE; BETA-LACTAMASE NDM-1; BISMUTH; CARBAPENEM DERIVATIVE; ORGANOMETALLIC COMPOUND; ZINC;

ANTIBIOTICS; BACTERIAL DISEASE; BACTERIUM; BISMUTH; DRUG; DRUG RESISTANCE; INHIBITION; INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL PERITONITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; IC50; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; X RAY CRYSTALLOGRAPHY; ANIMAL; BAGG ALBINO MOUSE; BETA-LACTAM RESISTANCE; CHEMISTRY; DOG; DRUG EFFECTS; ENZYME ACTIVE SITE; MDCK CELL LINE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR EVOLUTION; PERITONITIS; PRECLINICAL STUDY; PROCEDURES;

DELHI; INDIA; NEW DELHI;

BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; HELICOBACTER PYLORI; MUS;

ANIMALS; ANTI-INFECTIVE AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; BISMUTH; CARBAPENEMS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DOGS; DRUG EVALUATION, PRECLINICAL; EVOLUTION, MOLECULAR; FEMALE; MADIN DARBY CANINE KIDNEY CELLS; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; ORGANOMETALLIC COMPOUNDS; PERITONITIS; ZINC;

EID: 85041298939     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-02828-6     Document Type: Article

References (71)

1. Nordmann, P., Cuzon, G. & Naas, T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9, 228-236 (2009).
2. Fast, W. & Sutton, L. D. Metallo-β-lactamase: inhibitors and reporter substrates. Biochim. Biophys. Acta 1834, 1648-1659 (2013).
3. When the drugs don't work. Nat. Microbiol 1, 16003 (2016).
4. Cornaglia, G., Giamarellou, H. & Rossolini, G. M. Metallo-β-lactamases: a last frontier for beta-lactams? Lancet Infect. Dis. 11, 381-393 (2011).
5. Dortet, L., Poirel, L. & Nordmann, P. Worldwide dissemination of the NDMtype carbapenemases in Gram-negative bacteria. BioMed. Res. Int. 2014, 12 (2014).
6. Zmarlicka, M. T., Nailor, M. D. & Nicolau, D. P. Impact of the New Delhi metallo-β-lactamase on β-lactam antibiotics. Infect. Drug Resist. 8, 297-309 (2015).
7. Kumarasamy, K. K. et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10, 597-602 (2010).
8. Moellering, R. C. Jr. NDM-1 - a cause for worldwide concern. N. Engl. J. Med. 363, 2377-2379 (2010).
9. Nordmann, P., Poirel, L., Walsh, T. R. & Livermore, D. M. The emerging NDM carbapenemases. Trends Microbiol. 19, 588-595 (2011).
10. Livermore, D. M. et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother. 66, 48-53 (2011).
11. Berçot, B., Poirel, L. & Nordmann, P. Updated multiplex polymerase chain reaction for detection of 16S rRNA methylases: high prevalence among NDM-1 producers. Diagn. Microbiol. Infect. Dis. 71, 442-445 (2011).
12. Castanheira, M. et al. Early dissemination of NDM-1-and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY antimicrobial surveillance program, 2006-2007. Antimicrob. Agents Chemother. 55, 1274-1278 (2011).
13. Moellering, R. C. NDM-1 - a cause for worldwide concern. N. Engl. J. Med. 363, 2377-2379 (2010).
14. Drawz, S. M. & Bonomo, R. A. Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev. 23, 160-201 (2010).
15. Olsen, I. New promising β-lactamase inhibitors for clinical use. Eur. J. Clin. Microbiol. Infect. Dis. 34, 1303-1308 (2015).
16. Czaplewski, L. et al. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect. Dis. 16, 239-251 (2016).
17. Ejim, L. et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat. Chem. Biol. 7, 348-350 (2011).
18. Mojica, M. F., Bonomo, R. A. & Fast, W. B1-metallo-β-lactamases: where do we stand? Curr. Drug Targets 17, 1029-1050 (2016).
19. King, A. M. et al. Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance. Nature 510, 503-506 (2014).
20. Li, N. et al. Simplified captopril analogues as NDM-1 inhibitors. Bioorg. Med. Chem. Lett. 24, 386-389 (2014).
21. Klingler, F. M. et al. Approved drugs containing thiols as inhibitors of metallo-β-lactamases: strategy to combat multidrug-resistant bacteria. J. Med. Chem. 58, 3626-3630 (2015).
22. Brem, J. et al. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition. Nat. Chem. 6, 1084-1090 (2014).
23. Hinchliffe, P. et al. Cross-class metallo-β-lactamase inhibition by bisthiazolidines reveals multiple binding modes. Proc. Natl Acad. Sci. USA 113, E3745-E3754 (2016).
24. Chiou, J. et al. Ebselen as a potent covalent inhibitor of New Delhi metallo-β-lactamase (NDM-1). Chem. Commun. 51, 9543-9546 (2015).
25. Bebrone, C. et al. Current challenges in antimicrobial chemotherapy: focus on ss-lactamase inhibition. Drugs 70, 651-679 (2010).
26. Lemire, J. A., Harrison, J. J. & Turner, R. J. Antimicrobial activity of metals: mechanisms, molecular targets and applications. Nat. Rev. Microbiol. 11, 371-384 (2013).
27. Harbut, M. B. et al. Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc. Natl Acad. Sci. USA 112, 4453-4458 (2015).
28. Morones-Ramirez, J. R., Winkler, J. A., Spina, C. S. & Collins, J. J. Silver enhances antibiotic activity against gram-negative bacteria. Sci. Transl. Med. 5, 190ra181 (2013).
29. Antunes, L. C. S., Imperi, F., Minandri, F. & Visca, P. In vitro and in vivo antimicrobial activities of gallium nitrate against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 56, 5961-5970 (2012).
30. Chey, W. D., Leontiadis, G. I., Howden, C. W. & Moss, S. F. ACG clinical guideline: treatment of Helicobacter pylori infection. Am. J. Gastroenterol. 112, 212-239 (2017).
31. Gisbert, J. P. Helicobacter pylori eradication: a new, single-capsule bismuthcontaining quadruple therapy. Nat. Rev. Gastroenterol. Hepatol. 8, 307-309 (2011).
32. Reardon, S. Bacterial arms race revs up. Nature 521, 402-403 (2015).
33. Ho, P. L. et al. Complete sequencing of pNDM-HK encoding NDM-1 carbapenemase from a multidrug-resistant Escherichia coli strain isolated in Hong Kong. PLoS ONE 6, e17989 (2011).
34. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints - bacteria (v 7.0). EUCAST http://www.eucast.org (2017).
35. Petit, G. a. L. D. P. IUPAC Stability Constants Database (IUPAC/Academic Software, Otley, 1993).
36. Liang, Z. et al. Molecular basis of NDM-1, a new antibiotic resistance determinant. PLoS ONE 6, e23606 (2011).
37. Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84-87 (2013).
38. Jafari, R. et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 9, 2100-2122 (2014).
39. Yang, N. et al. Bismuth complexes inhibit the SARS coronavirus. Angew. Chem. Int. Ed. Engl. 46, 6464-6468 (2007).
40. Cun, S. & Sun, H. A zinc-binding site by negative selection induces metallodrug susceptibility in an essential chaperonin. Proc. Natl Acad. Sci. USA 107, 4943-4948 (2010).
41. Gonzalez, L. J. et al. Membrane anchoring stabilizes and favors secretion of New Delhi metallo-beta-lactamase. Nat. Chem. Biol. 12, 516-522 (2016).
42. Barry, N. P. & Sadler, P. J. Exploration of the medical periodic table: towards new targets. Chem. Commun. 49, 5106-5131 (2013).
43. Wang, Y. et al. Bio-coordination of bismuth in Helicobacter pylori revealed by immobilized metal affinity chromatography. Chem. Commun. 51, 16479-16482 (2015).
44. Li, H. & Sun, H. Recent advances in bioinorganic chemistry of bismuth. Curr. Opin. Chem. Biol. 16, 74-83 (2012).
45. Park, J. Y. et al. Establishment of experimental murine peritonitis model with hog gastric mucin for carbapenem-resistant Gram-negative bacteria. Infect. Chemother. 49, 57-61 (2017).
46. Jacoby, G. A. & Munoz-Price, L. S. The new β-lactamases. N. Engl. J. Med. 352, 380-391 (2005).
47. Palzkill, T. Metallo-β-lactamase structure and function. Ann. N. Y. Acad. Sci. 1277, 91-104 (2013).
48. Zmarlicka, M. T., Nailor, M. D. & Nicolau, D. P. Impact of the New Delhi metallo-β-lactamase on β-lactam antibiotics. Infect. Drug Resist. 8, 297-309 (2015).
49. Hong, Y., Lai, Y. T., Chan, G. C. & Sun, H. Glutathione and multidrug resistance protein transporter mediate a self-propelled disposal of bismuth in human cells. Proc. Natl Acad. Sci. USA 112, 3211-3216 (2015).
50. Wagstaff, A. J., Benfield, P. & Monk, J. P. Colloidal bismuth subcitrate. Drugs 36, 132-157 (1988).
51. Yang, N. & Sun, H. in Biological Chemistry of Arsenic, Antimony and Bismuth (ed. Sun, H.) 53-81 (John Wiley & Sons, Ltd., Chichester, 2011).
52. Zhang, H. & Hao, Q. Crystal structure of NDM-1 reveals a common β-lactam hydrolysis mechanism. FASEB J. 25, 2574-2582 (2011).
53. Bebrone, C. Metallo-β-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily. Biochem. Pharmacol. 74, 1686-1701 (2007).
54. Canton, R., Morosini, M. I., de la Maza, O. M. & de la Pedrosa, E. G. IRT and CMT β-lactamases and inhibitor resistance. Clin. Microbiol. Infect. 14, 53-62 (2008).
55. Papp-Wallace, K. M., Winkler, M. L., Taracila, M. A. & Bonomo, R. A. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam. Antimicrob. Agents Chemother. 59, 3710-3717 (2015).
56. Klauder, J. V. Intravenous injections of bismuth compounds in the treatment of syphilis: its use clinically and in experimental syphilis in rabbits. Arch. Dermatol. Syphilol. 17, 332-350 (1928).
57. Hanzlik, P. J., Lehman, A. J. & Richardson, A. P. Intramuscular injection of sobisminol: absorption and distribution of bismuth. J. Pharmacol. Exp. Ther. 62, 413-421 (1938).
58. Boer, W. A., Etten, R. J. X. M., Schneeberger, P. M. & Tytgat, G. N. J. A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule. Am. J. Gastroenterol. 95, 641-645 (2000).
59. Canena, J. et al. Distribution of bismuth in the rat after oral dosing with ranitidine bismuth citrate and bismuth subcitrate. J. Pharm. Pharmacol. 50, 279-283 (1998).
60. Brown, D. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? Nat. Rev. Drug Discov. 14, 821-832 (2015).
61. Hakkesteegt, J. A reaction for the determination of the identity of bismuthtetrabromocatechol. Pharm. Weekbl. 99, 922-924 (1964).
62. Ryan, D. K. & Weber, J. H. Fluorescence quenching titration for determination of complexing capacities and stability constants of fulvic acid. Anal. Chem. 54, 986-990 (1982).
63. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671-675 (2012).
64. Patel, J. B. et al. Performance Standards for Antimicrobial Susceptibility Testing. Report No. CLSI M100-S20 (Clinical and Laboratory Standards Institute, Wayne, PA, 2010).
65. Mathers, A. J. Antibiotics in laboratory medicine. Clin. Infect. Dis. 60, 1446-1447 (2015).
66. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
67. Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr 67, 355-367 (2011).
68. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr 66, 486-501 (2010).
69. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010).
70. Bogdanovich, T. et al. Antistaphylococcal activity of ceftobiprole, a new broadspectrum cephalosporin. Antimicrob. Agents Chemother. 49, 4210-4219 (2005).
71. Ling, L. L. et al. A new antibiotic kills pathogens without detectable resistance. Nature 517, 455-459 (2015).